The CTLs expressing activation markers CD69 and CD62L were also increased by greater than fourfold in the mIL12 mRNA-treated tumors compared to control tumors indicating an active CTL-mediated anti-tumor response environment (Fig. 5C). This evidence concerns the gene SELL and neoplasm.